CDK4/6 inhibitors have emerged as a pivotal component in the treatment of metastatic hormone receptor-positive breast cancer. These inhibitors are recognized as the standard of care, […]
Palbociclib (Ibrance) is a CDK4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC).